JP2019531092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531092A5 JP2019531092A5 JP2019536689A JP2019536689A JP2019531092A5 JP 2019531092 A5 JP2019531092 A5 JP 2019531092A5 JP 2019536689 A JP2019536689 A JP 2019536689A JP 2019536689 A JP2019536689 A JP 2019536689A JP 2019531092 A5 JP2019531092 A5 JP 2019531092A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligoribonucleotide
- sequence
- molecule
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091027075 5S-rRNA precursor Proteins 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 108091028664 Ribonucleotide Proteins 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 239000002336 ribonucleotide Substances 0.000 claims 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 208000037140 Steinert myotonic dystrophy Diseases 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 3
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 2
- 238000002638 palliative care Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 101000583839 Homo sapiens Muscleblind-like protein 1 Proteins 0.000 claims 1
- 101000583841 Homo sapiens Muscleblind-like protein 2 Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 102100030964 Muscleblind-like protein 2 Human genes 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201631216 | 2016-09-19 | ||
| ES201631216A ES2659845B1 (es) | 2016-09-19 | 2016-09-19 | Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello |
| PCT/EP2017/073685 WO2018050930A1 (en) | 2016-09-19 | 2017-09-19 | Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531092A JP2019531092A (ja) | 2019-10-31 |
| JP2019531092A5 true JP2019531092A5 (enExample) | 2019-12-12 |
| JP6919098B2 JP6919098B2 (ja) | 2021-08-18 |
Family
ID=59974404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536689A Active JP6919098B2 (ja) | 2016-09-19 | 2017-09-19 | 筋強直性ジストロフィー１型に対するマイクロｒｎａの変調及びそのためのマイクロｒｎａのアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11202794B2 (enExample) |
| EP (2) | EP4269587A3 (enExample) |
| JP (1) | JP6919098B2 (enExample) |
| AU (2) | AU2017328728B2 (enExample) |
| CA (1) | CA3037288C (enExample) |
| ES (1) | ES2659845B1 (enExample) |
| IL (1) | IL265461B2 (enExample) |
| WO (1) | WO2018050930A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI722310B (zh) | 2017-08-03 | 2021-03-21 | 美商航海家醫療公司 | 用於aav之遞送之組合物及方法 |
| JP7432929B2 (ja) * | 2018-05-31 | 2024-02-19 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途 |
| US20210340537A1 (en) * | 2020-04-15 | 2021-11-04 | Duquesne University Of The Holy Spirit | AN RNA G-QUADRUPLEX STRUCTURE IN PRE-miRNA-1229 AS A THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE AND VARIOUS CANCERS |
| ES2954008A1 (es) * | 2022-04-06 | 2023-11-17 | Univ Valencia | Antagonistas de los microRNA humanos miR-100, miR-20, miR-222, miR-181, y miR-92 y usos de los mismos |
| WO2023194641A1 (es) | 2022-04-06 | 2023-10-12 | Universitat De València | Antagonistas de los microrna humanos mir-100, mir-20, mir-222, mir-181, y mir-92 y usos de los mismos |
| EP4282964A1 (en) * | 2022-05-23 | 2023-11-29 | Universitat de Valéncia | Oligonucleotides conjugated to oleic acid and uses thereof |
| ES3014830A1 (es) * | 2023-10-20 | 2025-04-25 | Arthex Biotech S L | Oligonucleotidos o analogos de los mismos para el tratamiento de la distrofia del endotelio corneal de fuchs |
| CN117467664B (zh) * | 2023-11-07 | 2024-06-21 | 江苏省家禽科学研究所 | 一种靶向鸡mbnl1基因的反义寡核苷酸及其应用 |
| WO2025114442A1 (en) * | 2023-11-28 | 2025-06-05 | Arthex Biotech S.L. | Oligonucleotides conjugated to oleic acid and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| EP2298358A1 (en) | 2002-05-06 | 2011-03-23 | Alnylam Pharmaceuticals Inc. | Methods for delivery of nucleic acids |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| WO2005079397A2 (en) * | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
| WO2006069584A2 (en) * | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| JP5213723B2 (ja) * | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| EP2007889A2 (en) * | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| EP2066812A4 (en) * | 2006-09-21 | 2010-04-28 | Univ Rochester | COMPOSITIONS AND METHODS RELATED TO PROTEIN SHIFT THERAPY FOR MYOTONE DYSTROPHY |
| AU2008232316A1 (en) * | 2007-03-26 | 2008-10-02 | Newcastle Innovation Limited | Therapeutic targets and molecules |
| WO2009012263A2 (en) * | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| JPWO2009148137A1 (ja) | 2008-06-04 | 2011-11-04 | 協和発酵キリン株式会社 | 肥満細胞の脱顆粒を制御する核酸 |
| CA2777486A1 (en) * | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| US8852940B2 (en) * | 2009-04-01 | 2014-10-07 | The Regents Of The University Of California | Embryonic stem cell specific microRNAs promote induced pluripotency |
| US9320755B2 (en) | 2009-06-05 | 2016-04-26 | Centenary Institute Of Cancer Medicine And Cell Biology | Therapeutic and diagnostic molecules |
| EP2275545A1 (en) * | 2009-07-16 | 2011-01-19 | Julius-Maximilians-Universität Würzburg | Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis |
| US9340782B2 (en) | 2010-01-20 | 2016-05-17 | Board Of Regents, The University Of Texas System | Antimir-451 for the treatment of polycythemias |
| CA2805765A1 (en) * | 2010-07-19 | 2012-01-26 | C. Frank Bennett | Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
| US8729046B2 (en) * | 2011-12-07 | 2014-05-20 | Albert Einstein College Of Medicine Of Yeshiva University | MIR27B is a novel target for treatment of liver fibrosis |
| KR20130083965A (ko) * | 2012-01-16 | 2013-07-24 | 김승찬 | 시험관내 배양된 세포주 에 hsa-miR-218 miRNA에 대한 DNA antisense oligomer 처리 및 신호전달체계 변경 방법 |
| GB201202228D0 (en) | 2012-02-08 | 2012-03-28 | Queen Mary & Westfield College | Reversal of replicative senescence |
| AU2013248981B2 (en) * | 2012-04-20 | 2018-11-29 | Aptamir Therapeutics, Inc. | Mirna modulators of thermogenesis |
| WO2016091747A1 (en) | 2014-12-09 | 2016-06-16 | Pierfrancesco Tassone | Inhibitors of mir-17-92 cluster for anti-tumor activity in multiple myeloma and other malignancies |
-
2016
- 2016-09-19 ES ES201631216A patent/ES2659845B1/es active Active
-
2017
- 2017-09-19 JP JP2019536689A patent/JP6919098B2/ja active Active
- 2017-09-19 IL IL265461A patent/IL265461B2/en unknown
- 2017-09-19 EP EP23185838.2A patent/EP4269587A3/en active Pending
- 2017-09-19 EP EP17776976.7A patent/EP3516059A1/en active Pending
- 2017-09-19 CA CA3037288A patent/CA3037288C/en active Active
- 2017-09-19 WO PCT/EP2017/073685 patent/WO2018050930A1/en not_active Ceased
- 2017-09-19 US US16/334,725 patent/US11202794B2/en active Active
- 2017-09-19 AU AU2017328728A patent/AU2017328728B2/en active Active
-
2021
- 2021-10-25 AU AU2021257890A patent/AU2021257890A1/en not_active Abandoned
- 2021-11-12 US US17/525,672 patent/US20220133774A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531092A5 (enExample) | ||
| JP2023123491A5 (enExample) | ||
| FI3442602T3 (fi) | Mikrodystrofiinin anto adeno-assioituneella virusvektorilla lihasdystrofian hoitamiseksi | |
| JP2017070307A5 (enExample) | ||
| NZ701693A (en) | Composition and methods for highly efficient gene transfer using aav capsid variants | |
| JP2018533954A5 (enExample) | ||
| JP2015518713A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| MX2021010356A (es) | SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR. | |
| JP2016522674A5 (enExample) | ||
| WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
| JP2021500064A5 (enExample) | ||
| WO2013078199A3 (en) | Methods for enhanced in vivo delivery of synthetic, modified rnas | |
| JP2018512876A5 (enExample) | ||
| JP2015518711A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| EP3290055A3 (en) | Recombinant virus products and methods for inhibition of expression of dux4 | |
| FI3155017T3 (fi) | Parannettuja peptidilääkkeitä insuliiniresistenssiin | |
| NO20076013L (no) | Toksinpeptidterapeutiske midler | |
| JP2017006120A5 (enExample) | ||
| EA201990558A2 (ru) | ДОСТАВКА НАЦЕЛЕННЫХ НА ЭКЗОН 2 ПОЛИНУКЛЕОТИДНЫХ КОНСТРУКЦИЙ U7snRNA ПРИ ПОМОЩИ РЕКОМБИНАНТНОГО АДЕНОАССОЦИИРОВАННОГО ВИРУСА | |
| UA102993C2 (ru) | Анти-vegf единичный вариабельный домен иммуноглобулина | |
| IN2014DN00101A (enExample) | ||
| EA201591992A1 (ru) | Эффективная доставка больших генов посредством двойных aav векторов |